Lin H - Search Results

1

Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia.

Donato NJ, Wu JY, Stapley J, Lin H, Arlinghaus R, Aggarwal BB, Shishodia S, Albitar M, Hayes K, Kantarjian H, Talpaz M. Donato NJ, et al. Among authors: lin h. Cancer Res. 2004 Jan 15;64(2):672-7. doi: 10.1158/0008-5472.can-03-1484. Cancer Res. 2004. PMID: 14744784

2

Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent course.

Verstovsek S, Lin H, Kantarjian H, Saglio G, De Micheli D, Pane F, Garcia-Manero G, Intrieri M, Rotoli B, Salvatore F, Guo JQ, Talpaz M, Specchia G, Pizzolo G, Liberati AM, Cortes J, Quackenbush RC, Arlinghaus RB. Verstovsek S, et al. Among authors: lin h. Cancer. 2002 May 1;94(9):2416-25. doi: 10.1002/cncr.10490. Cancer. 2002. PMID: 12015767 Free article.

3

Jak2 is involved in c-Myc induction by Bcr-Abl.

Xie S, Lin H, Sun T, Arlinghaus RB. Xie S, et al. Among authors: lin h. Oncogene. 2002 Oct 17;21(47):7137-46. doi: 10.1038/sj.onc.1205942. Oncogene. 2002. PMID: 12370803

4

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R, Talpaz M. Donato NJ, et al. Among authors: lin h. Blood. 2003 Jan 15;101(2):690-8. doi: 10.1182/blood.V101.2.690. Blood. 2003. PMID: 12509383 Free article.

5

Bcr-Abl-mediated suppression of normal hematopoiesis in leukemia.

Lin H, Monaco G, Sun T, Ling X, Stephens C, Xie S, Belmont J, Arlinghaus R. Lin H, et al. Oncogene. 2005 May 5;24(20):3246-56. doi: 10.1038/sj.onc.1208500. Oncogene. 2005. PMID: 15735695

6

Janus kinase 2: a critical target in chronic myelogenous leukemia.

Samanta AK, Lin H, Sun T, Kantarjian H, Arlinghaus RB. Samanta AK, et al. Among authors: lin h. Cancer Res. 2006 Jul 1;66(13):6468-72. doi: 10.1158/0008-5472.CAN-06-0025. Cancer Res. 2006. PMID: 16818614

7

Inhibition of lipocalin 2 impairs breast tumorigenesis and metastasis.

Leng X, Ding T, Lin H, Wang Y, Hu L, Hu J, Feig B, Zhang W, Pusztai L, Symmans WF, Wu Y, Arlinghaus RB. Leng X, et al. Among authors: lin h. Cancer Res. 2009 Nov 15;69(22):8579-84. doi: 10.1158/0008-5472.CAN-09-1934. Epub 2009 Nov 3. Cancer Res. 2009. PMID: 19887608

8

WITHDRAWN: Requirement of lipocalin 2 in breast cancer.

Leng X, Ding T, Lin H, Wang Y, Wu Y, Arlinghaus RB. Leng X, et al. Among authors: lin h. Adv Enzyme Regul. 2009 Nov 13. doi: 10.1016/j.advenzreg.2009.10.001. Online ahead of print. Adv Enzyme Regul. 2009. PMID: 19914274 No abstract available.

9

Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells.

Nguyen T, Hawkins E, Kolluri A, Kmieciak M, Park H, Lin H, Grant S. Nguyen T, et al. Among authors: lin h. Leuk Res. 2015 Jan;39(1):65-71. doi: 10.1016/j.leukres.2014.10.009. Epub 2014 Nov 11. Leuk Res. 2015. PMID: 25465126 Free PMC article.

10

Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications.

Bjorklund CC, Baladandayuthapani V, Lin HY, Jones RJ, Kuiatse I, Wang H, Yang J, Shah JJ, Thomas SK, Wang M, Weber DM, Orlowski RZ. Bjorklund CC, et al. Among authors: lin hy. Leukemia. 2014 Feb;28(2):373-83. doi: 10.1038/leu.2013.174. Epub 2013 Jun 13. Leukemia. 2014. PMID: 23760401 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

32,982 results

Search Page

Filters